Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 7, 2011

Bristol-Myers Squibb Taps WuXi for Stability Testing

  • WuXi PharmaTech will conduct stability studies of small molecule NCEs for Bristol-Myers Squibb to support global marketing applications. Under the agreement WuXi will build, equip, and operate a dedicated, fully cGMP-compliant 25,000 square foot analytical testing facility in Shanghai.

    It will store and test stability samples and perform other services for BMS at this site. WuXi will also employ a dedicated staff for stability testing, sample management, analytical testing, pharmaceutical science, quality assurance, metrology, and other services including stability data reporting in support of all global dossier submissions by Bristol-Myers Squibb.

    “WuXi PharmaTech is an important partner for Bristol-Myers Squibb’s research and development organization,” notes Mark Powell, Ph.D., senior vice president, nonclinical development, Bristol-Myers Squibb. “This agreement will expand the scope of our relationship with WuXi and enhance the presence of Bristol-Myers Squibb in China.”



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »